US EditionNew hope for patients with less common breast cancer
- Researchers reported an interim analysis in 2025 showing a new treatment for HER2-positive metastatic breast cancer improved median progression-free survival in a global study.
- This study compared the new drug trastuzumab deruxtecan combined with pertuzumab against the current standard THP, which uses chemotherapy plus two antibodies, to target cancer growth signals.
- After 2.5 years, patients treated with both T-DXd and pertuzumab had a 44 percent lower chance of their cancer worsening or resulting in death, and 15 percent experienced complete remission of their cancer.
- An interim analysis showed that patients receiving the new therapy experienced a median progression-free survival of 40.7 months, compared to 26.9 months for those treated with the standard THP regimen, with oncologist Sara Tolaney noting this represents nearly twice the duration of cancer control.
- The results, deemed a new first-line standard treatment option, will be submitted to regulators worldwide and may improve outcomes for this less common breast cancer subtype lacking major drug advances over a decade.
25 Articles
25 Articles
I told everyone I had breast cancer. If you speak openly about it, you don’t have to go through it on your own
When a cancer patient who has endured successive rounds of gruelling treatment finally receives the all clear, relief is usually their predominant emotion. However, the journey of convalescence is not always smooth sailing.
#Hope on the Horizon Positive Phase 1b Data for Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negati...
At the recent American Society of Clinical Oncology (ASCO) 2025 meeting, Cardiff Oncology presented promising results from an investigator-initiated Phase 1b clinical trial evaluating the combination of onvansertib and paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). This aggressive form of breast cancer, known for its resistance to standard therapies and poor prognosis, has propelled researchers to seek innovative t…
A new treatment reduces the risk of progression by nearly 50% and even dozens due to a certain form of breast cancer, for which significant therapeutic progress has not been made over 10 years.
Coverage Details
Bias Distribution
- 54% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
